CGM Market – Q4 2022 Update & Commercial Execution

  • Public Equity
  • Healthcare
  • North America


Former regional leader at Abbott Laboratories


  • Recent trends and developments within the broader diabetes and CGM (continuous glucose monitor) industry
  • Comparative analysis of Dexcom’s (NASDAQ: DXCM) G7 and Abbott’s (NYSE: ABT) FreeStyle Libre 3 franchise
  • Sensor usage timeline and cost-reduction advantages of extending wear time
  • Type 2 diabetes awareness and adoption strategies utilised by organisations to drive further CGM penetration
  • Relative sales force reputations and execution in CGM product placements
  • 2023 M&A outlook, untapped growth opportunities and strategic assessments


Gain access to Premium Content

Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.

    One week, unlimited access to over 40,000 transcripts
The information, material and content contained in this transcript (“Content”) is for information purposes only and does not constitute advice of any type or a trade recommendation and should not form the basis of any investment decision.This transcript has been edited by Third Bridge for ease of reading. Third Bridge Group Limited and its affiliates (together “Third Bridge”) make no representation and accept no liability for the Contentor for any errors, omissions or inaccuracies in respect of it. The views of the specialist expressed in the Content are those of the specialist and they are not endorsed by, nor do they represent the opinion of, Third Bridge. Third Bridge reserves all copyright, intellectual and other property rights in the Content. Any modification, reformatting, copying, displaying, distributing, transmitting, publishing, licensing, creating derivative works from, transferring or selling any Content is strictly prohibited